389 related articles for article (PubMed ID: 28951518)
1. Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
Yi JS; Ready N; Healy P; Dumbauld C; Osborne R; Berry M; Shoemaker D; Clarke J; Crawford J; Tong B; Harpole D; D'Amico TA; McSherry F; Dunphy F; McCall SJ; Christensen JD; Wang X; Weinhold KJ
Clin Cancer Res; 2017 Dec; 23(24):7474-7482. PubMed ID: 28951518
[No Abstract] [Full Text] [Related]
2. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
3. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
[TBL] [Abstract][Full Text] [Related]
6. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
Tang C; Welsh JW; de Groot P; Massarelli E; Chang JY; Hess KR; Basu S; Curran MA; Cabanillas ME; Subbiah V; Fu S; Tsimberidou AM; Karp D; Gomez DR; Diab A; Komaki R; Heymach JV; Sharma P; Naing A; Hong DS
Clin Cancer Res; 2017 Mar; 23(6):1388-1396. PubMed ID: 27649551
[No Abstract] [Full Text] [Related]
8. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
Govindan R; Szczesna A; Ahn MJ; Schneider CP; Gonzalez Mella PF; Barlesi F; Han B; Ganea DE; Von Pawel J; Vladimirov V; Fadeeva N; Lee KH; Kurata T; Zhang L; Tamura T; Postmus PE; Jassem J; O'Byrne K; Kopit J; Li M; Tschaika M; Reck M
J Clin Oncol; 2017 Oct; 35(30):3449-3457. PubMed ID: 28854067
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
Pujol JL; Vansteenkiste JF; De Pas TM; Atanackovic D; Reck M; Thomeer M; Douillard JY; Fasola G; Potter V; Taylor P; Bosquée L; Scheubel R; Jarnjak S; Debois M; de Sousa Alves P; Louahed J; Brichard VG; Lehmann FF
J Thorac Oncol; 2015 Oct; 10(10):1458-67. PubMed ID: 26309191
[TBL] [Abstract][Full Text] [Related]
11. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Tarhini AA; Edington H; Butterfield LH; Lin Y; Shuai Y; Tawbi H; Sander C; Yin Y; Holtzman M; Johnson J; Rao UN; Kirkwood JM
PLoS One; 2014; 9(2):e87705. PubMed ID: 24498358
[TBL] [Abstract][Full Text] [Related]
12. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
13. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.
Sepesi B; Zhou N; William WN; Lin HY; Leung CH; Weissferdt A; Mitchell KG; Pataer A; Walsh GL; Rice DC; Roth JA; Mehran RJ; Hofstetter WL; Antonoff MB; Rajaram R; Negrao MV; Tsao AS; Gibbons DL; Lee JJ; Heymach JV; Vaporciyan AA; Swisher SG; Cascone T
J Thorac Cardiovasc Surg; 2022 Nov; 164(5):1327-1337. PubMed ID: 35190177
[TBL] [Abstract][Full Text] [Related]
14. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Cascone T; William WN; Weissferdt A; Leung CH; Lin HY; Pataer A; Godoy MCB; Carter BW; Federico L; Reuben A; Khan MAW; Dejima H; Francisco-Cruz A; Parra ER; Solis LM; Fujimoto J; Tran HT; Kalhor N; Fossella FV; Mott FE; Tsao AS; Blumenschein G; Le X; Zhang J; Skoulidis F; Kurie JM; Altan M; Lu C; Glisson BS; Byers LA; Elamin YY; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Roth JA; Antonoff MB; Kadara H; Haymaker C; Bernatchez C; Ajami NJ; Jenq RR; Sharma P; Allison JP; Futreal A; Wargo JA; Wistuba II; Swisher SG; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Sepesi B
Nat Med; 2021 Mar; 27(3):504-514. PubMed ID: 33603241
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
17. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
18. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
Feldman H; Sepesi B; Leung CH; Lin H; Weissferdt A; Pataer A; William WN; Walsh GL; Rice DC; Roth JA; Mehran RJ; Hofstetter WL; Antonoff MB; Rajaram R; Gibbons DL; Lee JJ; Heymach JV; Vaporciyan AA; Swisher SG; Cascone T
J Thorac Cardiovasc Surg; 2024 Apr; 167(4):1444-1453.e4. PubMed ID: 37816395
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
[TBL] [Abstract][Full Text] [Related]
20. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
